August 24, 2023

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Abata in the News

Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events

Press Release
August 28, 2023

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Press Release
May 31, 2023

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Press Release
April 20, 2023

We Now Know the Enemy: A Conversation with Richard Ransohoff, M.D. Featuring John Maraganore, Ph.D.

Abata Video
April 10, 2023

Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity

Trends in Immunology
March 30, 2023

Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors

March 9, 2023

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Press Release
December 14, 2022

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

Press Release
December 7, 2022

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day  

Press Release
November 9, 2022

Samantha Singer Named as 2022 PharmaVoice 100 Honoree

September 8, 2022